medisourceasia.com

Industry News


About 
medisourceasia

Magazine
Industry News
Global Trends
Events Calendar
Web Links

Web Gallery

Advertising  Info

Contact

 

US FDA revises communication regulation to drug companies on applications

The US Food and Drug Administration is revising the way it communicates to drug companies when a marketing application cannot be approved as submitted.

Under new regulations that govern the drug approval process, FDA's Center for Drug Evaluation and Research (CDER) will no longer issue "approvable" or "not approvable" letters when a drug application is not approved. Instead, CDER will issue a "complete response" letter at the end of the review period to let a drug company know of the agency's decision on the application, a FDA press release said.

"These new regulations will help the FDA adopt a more consistent and neutral way of conveying information to a company when we cannot approve a drug application in its present form," said Janet Woodcock, M.D., director of the agency's Center for Drug Evaluation and Research (CDER). "Thorough and timely review of drug applications is a priority of the FDA, and these new processes will make our communications with sponsors of applications more consistent."

Taking the place of "approvable" and "not approvable" letters, a "complete response" letter will be issued to let a company know that the review period for a drug is complete and that the application is not yet ready for approval. The letter will describe specific deficiencies and, when possible, will outline recommended actions the applicant might take to get the application ready for approval.

Currently, when assessing new drug applications, the FDA can respond to a sponsor in one of three types of letters: an "approval" letter, meaning the drug has met agency standards for safety and efficacy and the drug can be marketed for sale in the United States; an "approvable" letter, which generally indicates that the drug can probably be approved at a later date provided that the applicant provides certain additional information or makes specified changes (such as to labelling); or a "not approvable" letter, meaning the application has deficiencies generally requiring the submission of substantial additional data before the application can be approved.

"Complete response" letters are already used to respond to companies that submit biologic license applications. The process for drugs and biologics will be consistent under the new regulations.

The revision should not affect the overall time it takes the FDA to review new or generic drug applications or biologic license applications. These changes, which will become effective on Aug. 11, 2008, are not expected to directly affect consumers.

In July 2004, the FDA issued a proposed rule on these topics. At that time the agency asked for comments on the proposal. Today's final rule addresses comments submitted to the agency.

(Ref: Chronicle Pharmabiz dated 12 July 2008)

Other News

Gujarat To Bolster Healthcare Sector
CII To Organize Seminars On Regulation On Medical Devices
Conference Theme For Next Delhi IPC: “Regulation For Better Healthcare”
B Braun Launches Coroflex Please Drug Eluting Stent In India
HLL, IL&FS Ink Mou For An Integrated Medical Devices And Diagnostic Manufacturing Park
Govt. To Finance Center Of Excellence For Medical Textiles
Kehlescope, A Tongue Depressor For Examining The Oral Cavity, Invented By Indian Doctors
Productivity Council finds 40% SSI units shut due to enforcement of GMP norms
US FDA to establish offices in Delhi, Mumbai, Hyderabad soon
Spurious drugs bill to be moved in next session of parliament
Dr Batra's launches first tele-homeopathic clinic at Mumbai
Centre allots Rs 630 cr for medicinal plants cultivation covering one lakh hectares
DCGI warns illegal units making medical devices, directs to obtain licenses
DCGI to establish multi-level complaint redressal system to address industry grievances
GE Sensing develops Labwatch monitoring system for pharma-biotech sector
CCE Software develops two new solutions for Pharma ERP and Medical Rep Management
Welch Allyn launches FlexiPort blood pressure cuffs

Archives

Advertisement

 

 


Back | Back To Top | Previous